Dr. Armand Keating, Director of Hematology at Toronto’s Princess Margaret Hospital, part of the University Health Network (UHN), has been leading some groundbreaking research on the use of natural killer cell lines in the treatment of blood cancers. Having demonstrated the effectiveness of one particular natural killer cell line, NK-92, in various in-vitro studies, Dr. Keating and his research team were ready to progress to the next stage of investigation.

The Jesse & Julie Rasch Foundation has granted funds to the Cell Therapy Program at UHN to aid Dr. Keating in the completion of his series of NK-92 Clinical Trials. The Foundation would like to see Dr. Keating drive progress across the realm of cell therapy investigation and advance research that impacts our understanding and treatment of lymphoma, leukemia and other blood cancers.